Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Biotech
Arch-backed obesity biotech launches with $290M
Clinical-stage Metsera has emerged from stealth with $290 million and the bold vision of ushering in the next generation of obesity treatments.
Gabrielle Masson
Apr 18, 2024 7:00am
Novartis only wanted pelabresib, but MorphoSys had other ideas
Apr 12, 2024 8:53am
Novartis pays $150M for Arvinas' prostate tumor protein degrader
Apr 11, 2024 8:04am
Top 10 pharma R&D budgets in 2023
Mar 18, 2024 5:00am
Novartis hits the cGAS, taking up option to buy IFM unit
Mar 13, 2024 9:01am
Novartis lines up another potential indication for BTK inhibitor
Mar 9, 2024 12:00pm